MX2010012019A - Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2. - Google Patents

Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.

Info

Publication number
MX2010012019A
MX2010012019A MX2010012019A MX2010012019A MX2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A MX 2010012019 A MX2010012019 A MX 2010012019A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
pharmaceutical product
muscarinic receptor
adrenoceptor agonist
active ingredient
Prior art date
Application number
MX2010012019A
Other languages
English (en)
Spanish (es)
Inventor
Mete Antonio
Ford Rhonan
Mather Andrew
Wiley Katherine
James Bull Richard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808710A external-priority patent/GB0808710D0/en
Priority claimed from GB0900563A external-priority patent/GB0900563D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2010012019A publication Critical patent/MX2010012019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2010012019A 2008-05-13 2009-05-12 Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2. MX2010012019A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0808710A GB0808710D0 (en) 2008-05-13 2008-05-13 New combination 296
GB0900563A GB0900563D0 (en) 2009-01-14 2009-01-14 New combination
PCT/SE2009/050525 WO2009139708A1 (en) 2008-05-13 2009-05-12 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST

Publications (1)

Publication Number Publication Date
MX2010012019A true MX2010012019A (es) 2011-03-04

Family

ID=41318921

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012019A MX2010012019A (es) 2008-05-13 2009-05-12 Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.

Country Status (11)

Country Link
US (1) US20110190309A1 (enExample)
EP (1) EP2315589A4 (enExample)
JP (1) JP2011520877A (enExample)
KR (1) KR20110010725A (enExample)
CN (2) CN102908624A (enExample)
AU (1) AU2009247021B2 (enExample)
BR (1) BRPI0912657A2 (enExample)
CA (1) CA2723909A1 (enExample)
MX (1) MX2010012019A (enExample)
RU (1) RU2010147881A (enExample)
WO (1) WO2009139708A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
JP4837800B2 (ja) 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
KR101845257B1 (ko) 2011-02-07 2018-04-04 삼성전자주식회사 이미지 센서
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (enExample) * 1942-12-16
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
US6223485B1 (en) * 1996-06-07 2001-05-01 Herman Miller, Inc. Wall panel system
KR20000029703A (ko) * 1996-07-29 2000-05-25 존 헤덴스트룀 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법
US6613795B2 (en) * 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
WO2002096855A2 (en) * 2001-04-03 2002-12-05 Aryx Therapeutics Anticholinergic compounds and methods of use
US7056916B2 (en) * 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
TW200738658A (en) * 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) * 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) * 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702456D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) * 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0704000D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
JP4837800B2 (ja) * 2008-05-13 2011-12-14 アストラゼネカ・アクチエボラーグ ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体

Also Published As

Publication number Publication date
CN102088976A (zh) 2011-06-08
KR20110010725A (ko) 2011-02-07
AU2009247021B2 (en) 2012-06-07
US20110190309A1 (en) 2011-08-04
CN102908624A (zh) 2013-02-06
JP2011520877A (ja) 2011-07-21
EP2315589A1 (en) 2011-05-04
RU2010147881A (ru) 2012-06-20
CN102088976B (zh) 2012-12-26
EP2315589A4 (en) 2013-09-11
BRPI0912657A2 (pt) 2016-01-26
AU2009247021A1 (en) 2009-11-19
CA2723909A1 (en) 2009-11-19
WO2009139708A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
MY178634A (en) Topical formulation for a jak inhibitor
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
WO2007106181A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
IL189499A (en) Use of 2,4-diaminopyrimidines or 4-aminopyrimidines for the preparation of a medicament for the treatment of a respiratory disease mediated by a p2x3 or p2x2/3 receptor antagonist
IL184932A0 (en) Glucagon receptor antagonists, preperation and therapeutic uses
IL233677A (en) Benzysacazole Compounds Aminopyrazolo-Primidine Converted, Pharmaceuticals Containing Them, and Use of Drug Manufacturing Composition
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
MY207466A (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
GEP20186839B (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
IL200822A (en) Compound of (s) –2– Amino – 1– (4 – Chlorophenyl) –1– [4– (h1– Pyrazole-4-ram) -Phenyl] -ethanol Diseases mediated by some protein kinases
WO2007120270A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2007120284A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses
MX2010012019A (es) Producto farmaceutico que comprende un antagonista receptor muscarinico y un agonista de adrenoceptor beta2.
EP2323656A4 (en) PHARMACEUTICAL PRODUCT USING A MUSCARIN RECEPTOR ANTAGONIST AND A BETA-2 ADRENOZEPTORAGONIST
WO2010033167A3 (en) Anti-thrombin aptamer formulations and methods for use
EA200802104A1 (ru) Применение композиций, содержащих антагонисты каппа-опиоидных рецепторов, для лечения диссоциативных расстройств
WO2007114855A3 (en) Glucagon receptor antagonists, preparation and therapeutic uses

Legal Events

Date Code Title Description
FG Grant or registration